Last Updated on October 17, 2024 by The Health Master
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brexpiprazole tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, the company notified via a statement.
The statement also said that Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) and for treatment of schizophrenia.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
USFDA to review use of Blood Disorder Therapy in children
Aleor gets USFDA final approval for Metronidazole gel
Dr Reddy’s Labs gets USFDA nod for generic Librax capsules
Granules India gets Health Canada nod for drug for Arthritis pain
Sun Pharma gets exclusive right for Winlevi acne cream in US,…
Aurobindo Pharma gets USFDA nod for cancer treatment drug
New laws to be framed for Drugs, Cosmetics, Medical Devices
Govt may impose anti dumping duty on import of vitamin C…
USFDA to review use of Blood Disorder Therapy in children
B-Hub: Biopharma Hub to come up at Hyderabad’s Genome Valley
DCGI grants EUA to Truenat for Nipah virus tests in India
Latest Notifications regarding Pharmaceuticals
